 |
5 Diseases |  |
9 Trials |
|
9 Trials |  |
228 News |  |
| «123456789101112» |
- || odronextamab (REGN1979) / Regeneron, Lunsumio (mosunetuzumab) / Roche, Biogen
Review, Journal: The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma. (Pubmed Central) - May 31, 2022
These therapies include allogeneic CAR-T treatments and multi-antigen targeting therapies such as the CD19/CD22 CAR-T and the CD3/CD20 bispecific antibodies mosunetuzumab and odronextamab. We summarize our approach based on the best available evidence as we enter 2022.
- | Brukinsa (zanubrutinib) / BeiGene, Lunsumio (mosunetuzumab-axgb) / Roche
Enrollment open: A Study of Mosunetuzumab in People With Follicular Lymphoma (clinicaltrials.gov) - May 30, 2022
P2, N=53, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
We summarize our approach based on the best available evidence as we enter 2022. Not yet recruiting --> Recruiting
- ||| Lunsumio (mosunetuzumab-axgb) / Roche, tiragolumab (RG6058) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment open: An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - May 30, 2022
P1/2, N=118, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Lunsumio (mosunetuzumab) / Roche, Biogen
Clinical: 👀 Have you seen this? During #ASH2021, the #LymphomaHub spoke with @elizabeth_budde, @cityofhope. We asked, What results have you seen with mosunetuzumab in patients with high-risk #FL? 👉 https://t.co/0uVVdeLUlw 👈 #lymsm #lymphoma (Twitter) - May 25, 2022
- | Brukinsa (zanubrutinib) / BeiGene, Lunsumio (mosunetuzumab-axgb) / Roche
New P2 trial: A Study of Mosunetuzumab in People With Follicular Lymphoma (clinicaltrials.gov) - May 24, 2022
P2, N=53, Not yet recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- || lenalidomide / Generic mfg., Lunsumio (mosunetuzumab) / Roche, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Mosunetuzumab: • A phase 1 study by @elizabeth_budde et al in R/R B-NHL showed durable CRs; 1.0% g3+ CRS. https://t.co/2VJvhnxD5s • At #ASCO22, @LNastoupilMD will present CELESTIMO, a phase 3 trial of mosunetuzumab plus lenalidomide vs rituximab plus len in R/R FL (Twitter) - May 15, 2022
- Lunsumio (mosunetuzumab) / Roche, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA () - May 13, 2022 - Abstract #EHA2022EHA_1854;
P1/2, P3
Conclusion The study started recruitment in 2021 and plans to enroll ~400 patients from approximately 16 countries and 150 sites globally. Further study details will be presented.
- Lunsumio (mosunetuzumab) / Roche, Biogen
REAL WORLD DATA (RWD) AMONG FOLLICULAR LYMPHOMA (FL) PATIENTS IN GERMANY WITH AT LEAST TWO PRIOR LINES OF SYSTEMIC THERAPY AND COMPARISON WITH CLINICAL DATA FOR MOSUNETUZUMAB () - May 13, 2022 - Abstract #EHA2022EHA_1543;
P=N/A, P1/
TLNext outcomes data will be re-weighted using the MAIC approach to generate a descriptive benchmark for outcomes observed in M SAT. While comparisons between clinical trials and RWD carry several limitations pertaining to measurement, reporting of data, and choice of analytical approach to conduct the comparison, RWD from TLNext may be useful to describe a benchmark for clinical practice in 3L+ FL in Germany and globally prior to the availability of randomized evidence on newer treatment options like mosunetuzumab.
- Lunsumio (mosunetuzumab) / Roche, Biogen
MOSUNETUZUMAB RETREATMENT IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA () - May 13, 2022 - Abstract #EHA2022EHA_1518;
P1/2
Conclusion Our results show that IV M mono retreatment was efficacious in heavily pretreated pts with R/R NHL who initially achieved a CR with M treatment, but subsequently developed PD. M retreatment had a manageable safety profile, consistent with the initial treatment.
- Lunsumio (mosunetuzumab) / Roche, Biogen
MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY () - May 13, 2022 - Abstract #EHA2022EHA_1517;
P1/2
Conclusion Mosunetuzumab is efficacious and well tolerated in older and younger pts with R/R FL and ≥2 prior therapies. In older pts (aged ≥65 years), numerically lower rates of CRS and serious AEs were observed.
- || Review, Journal: Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment. (Pubmed Central) - Apr 30, 2022
However, several CD20 × CD3 BsAbs including odronextamab, mosunetuzumab, glofitamab, and epcoritamab emerged recently...In addition, how do BsAbs compare to CAR T-cell therapy and how to choose and sequence between BsAbs and CAR T-cell therapy need to be addressed. While many of these critical questions remain to be answered in clinical studies, we believe the future of BsAbs in the NHL is very bright.
- Lunsumio (mosunetuzumab) / Roche, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
CELESTIMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received ≥ 1 line of systemic therapy. (Available On Demand; 235b) - Apr 28, 2022 - Abstract #ASCO2022ASCO_2693;
P1, P1/2,
Biomarkers predictive of response to M-Len and R-Len will also be investigated as exploratory endpoints. The study started recruitment in 2021 and plans to enroll ̃400 patients from approximately 16 countries and 150 sites globally.
- Lunsumio (mosunetuzumab) / Roche, Biogen
Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphomas. (Available On Demand; 180) - Apr 28, 2022 - Abstract #ASCO2022ASCO_2633;
P1/2
The study started recruitment in 2021 and plans to enroll ̃400 patients from approximately 16 countries and 150 sites globally. In pts with R/R B-NHL treated with M, low BL CD20 expression is associated with lack of response to M. During M tx, loss of tumor cell expression of CD20 is one mechanism of acquired resistance; however, CD20 expression is maintained in most pts with PD, implying alternative mechanisms for acquired M resistance.
- |||| Lunsumio (mosunetuzumab) / Roche, Biogen
Clinical: "“Mosunetuzumab achieved durable complete responses in subjects with aggressive and indolent relapsed or refractory B-cell non-Hodgkin lymphomas.” -Syed Ali Abutalib, MD, and Matt Lunning, DO, FACP" https://t.co/2Q3DfPt3MG via @ascopost (Twitter) - Apr 25, 2022
- mosunetuzumab (RG7828) / Roche, Biogen
Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study () - Apr 25, 2022 - Abstract #BSH2022BSH_104;
P1
M + Len appears to have an acceptable safety profile in R/R FL pts with ≥1 prior therapy line and encouraging preliminary anti-lymphoma activity. These data support initiation of a randomised Phase III study of M + Len versus rituximab+Len.
- mosunetuzumab (RG7828) / Roche, Biogen
Mosunetuzumab Monotherapy is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory Follicular Lymphoma who have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study (Exchange Auditorium) - Apr 25, 2022 - Abstract #BSH2022BSH_27;
P1/2
Mosun had a manageable safety profile; C1 step-up dosing mitigated CRS, enabling treatment without mandatory hospitalisation. 3L+R/R FL, pts with relapsed/refractory follicular lymphoma who have received ≥2 prior therapy lines; Ab, antibody; CI, confidence interval; CR, complete response; ORR, objective response rate; PET/CT, positron emission tomography/computed tomography; POD24, progression of disease within 24 months from the start of initial therapy; pts, patients.
- ||| Zynlonta (loncastuximab tesirine-lpyl) / Overland ADCT BioPharma
Enrollment open: LOTIS 7: A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) (clinicaltrials.gov) - Apr 24, 2022
P1b, N=200, Recruiting, Sponsor: ADC Therapeutics S.A.
3L+R/R FL, pts with relapsed/refractory follicular lymphoma who have received ≥2 prior therapy lines; Ab, antibody; CI, confidence interval; CR, complete response; ORR, objective response rate; PET/CT, positron emission tomography/computed tomography; POD24, progression of disease within 24 months from the start of initial therapy; pts, patients. Not yet recruiting --> Recruiting
- | mosunetuzumab (RG7828) / Roche, Biogen
$RHHBY mosunetuzumab just got CHMP recommendation for EU conditional approval. Will likely beat US to the punch. (Twitter) - Apr 22, 2022
- | Lunsumio (mosunetuzumab-axgb) / Roche
Trial completion date, Trial primary completion date: BrUOG 401: Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma (clinicaltrials.gov) - Apr 19, 2022
P2, N=52, Not yet recruiting, Sponsor: Brown University
Not yet recruiting --> Recruiting Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2024 --> Aug 2025
- |||| Lunsumio (mosunetuzumab-axgb) / Roche, tiragolumab (RG6058) / Roche, Tecentriq (atezolizumab) / Roche
New P1/2 trial: An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Apr 6, 2022
P1/2, N=118, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | Polivy (polatuzumab vedotin-piiq) / Roche, Lunsumio (mosunetuzumab-axgb) / Roche
Trial completion date, Monotherapy: GO40554: Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Apr 6, 2022
P1/2, N=188, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2024 --> Aug 2025 Trial completion date: Sep 2025 --> Feb 2024
- LE13. AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology Lecture (Room 243-245, Convention Center) - Apr 5, 2022 - Abstract #AACR2022AACR_8220;
He is being recognized for paramount advances in cell biology, including the discovery of endosomes and applying these insights to understanding the immune response, and for demonstrating how dendritic cell maturation regulates the balance between immunity and tolerance. He has elucidated the mechanism of the PD-L1/PD-1 signaling pathway and the conceptualization of the Cancer Immunity Cycle, bringing atezolizumab to the clinic, and overseeing the discovery and development of iNeST-RNA, tiragolumab (anti-TIGIT), cobimetinib, mosunetuzumab, and a variety of other therapeutics currently in early stages of clinical investigation.
- ||||| mosunetuzumab (RG7828) / Roche, Biogen
Clinical: Also this AM learned about a new @BrownOncology clinical trial created by @lymphomatic for frontline follicular and marginal zone lymphoma. Really liked this slide which is a pic in the patient consent that shows how Mosunetuzumab works. Genius. (Twitter) - Mar 30, 2022
- |||||| Polivy (polatuzumab vedotin-piiq) / Roche, Lunsumio (mosunetuzumab-axgb) / Roche, Rituxan (rituximab) / Roche
Enrollment open: SUNMO: A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 25, 2022
P3, N=222, Recruiting, Sponsor: Hoffmann-La Roche
He has elucidated the mechanism of the PD-L1/PD-1 signaling pathway and the conceptualization of the Cancer Immunity Cycle, bringing atezolizumab to the clinic, and overseeing the discovery and development of iNeST-RNA, tiragolumab (anti-TIGIT), cobimetinib, mosunetuzumab, and a variety of other therapeutics currently in early stages of clinical investigation. Not yet recruiting --> Recruiting
- || Lunsumio (mosunetuzumab-axgb) / Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date: GO29781: A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Mar 18, 2022
P1/2, N=836, Recruiting, Sponsor: Genentech, Inc.
Not yet recruiting --> Recruiting Trial completion date: Nov 2023 --> Mar 2023 | Trial primary completion date: Nov 2023 --> Mar 2023
- || Polivy (polatuzumab vedotin-piiq) / Roche, Lunsumio (mosunetuzumab-axgb) / Roche
Trial completion date, Trial primary completion date: GO40516: A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 18, 2022
P1/2, N=262, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Nov 2023 --> Mar 2023 | Trial primary completion date: Nov 2023 --> Mar 2023 Trial completion date: Apr 2024 --> Nov 2023 | Trial primary completion date: Apr 2024 --> Jun 2023
- | Lunsumio (mosunetuzumab-axgb) / Roche
Trial completion date: CO41942: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma (clinicaltrials.gov) - Mar 11, 2022
P1, N=102, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Apr 2024 --> Nov 2023 | Trial primary completion date: Apr 2024 --> Jun 2023 Trial completion date: Jul 2024 --> Mar 2026
- || Polivy (polatuzumab vedotin-piiq) / Roche, Lunsumio (mosunetuzumab-axgb) / Roche, Gazyva (obinutuzumab) / Roche, Biogen
Enrollment open: NCI-2021-12489: Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 4, 2022
P2, N=42, Recruiting, Sponsor: University of Washington
Trial completion date: Jul 2024 --> Mar 2026 Not yet recruiting --> Recruiting
- || Polivy (polatuzumab vedotin-piiq) / Roche, Lunsumio (mosunetuzumab-axgb) / Roche
New P2 trial, CAR T-Cell Therapy: CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). (clinicaltrials.gov) - Mar 2, 2022
P2, N=40, Not yet recruiting, Sponsor: Lazaros Lekakis
- || mosunetuzumab (RG7828) / Roche, Biogen
Clinical, P1 data, Journal: Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. (Pubmed Central) - Feb 22, 2022
P1/2
Mosunetuzumab, administered with step-up dosing, has a manageable safety profile and induces durable complete responses in R/R B-NHL. The expansion stage of the study is ongoing at the dose level of 1/2/60/60/30 mg selected for further study.
- | mosunetuzumab (RG7828) / Roche
This is quite the ricochet. A deal done 27 years ago results in $BIIB oping in to $RHHBY mosunetuzumab today (Twitter) - Feb 1, 2022
- ||||| mosunetuzumab (RG7828) / Roche
Video: Did you catch @DrMatasar's lymphoma update from ASH 2021? His highlights include POLARIX, CAR-T in LBCL and mosunetuzumab in FL. Watch the short video & download the slides: https://t.co/MmzV0alCC5 #lymsm #MedEd #lymphoma #HemOnc #hematology #ASH21 (Twitter) - Jan 31, 2022
- ||||| Lunsumio (mosunetuzumab-axgb) / Roche
New P2 trial, Monotherapy: MorningSun: A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (clinicaltrials.gov) - Jan 25, 2022
P2, N=275, Recruiting, Sponsor: Genentech, Inc.
- | mosunetuzumab (RG7828) / Roche
Linfoma follicolare recidivato/refrattario, #mosunetuzumab migliora il tasso di risposta. #ASH21 https://t.co/iKoXn5c0kI (Twitter) - Jan 24, 2022
- || mosunetuzumab (RG7828) / Roche
複数治療歴のある再発/難治性 #濾胞性リンパ腫（#FL）患者さんにを対象にCD3とCD20を標的とする二特異性抗体 #Mosunetuzumab（#モスネツズマブ）単剤療法の有効性、安全性を検証した第1/2相試験（#NCT02500407）の結果が第63回米国血液学会（#ASH2021）にて公表されました。 https://t.co/g2nHXPj7uG (Twitter) - Jan 19, 2022
P1/2
- ||||| mosunetuzumab (RG7828) / Roche
Video: Here, @DrMatasar shares his roundup of the highlights in #lymphoma from #ASH21, including POLARIX, CAR-T in LBCL and mosunetuzumab in FL. Watch the 5-minute video and download the accompanying slides: https://t.co/dUziqq3IH3 #MedEd #lymsm (Twitter) - Jan 17, 2022
- ||||| mosunetuzumab (RG7828) / Roche
Video: Medical Oncologist Dr. Matthew Matasar @DrMatasar summarises the highlights in #lymphoma from #ASH21, including POLARIX, CAR-T in LBCL and mosunetuzumab in FL. Watch the video and download slides: https://t.co/u70mkzpMHn #hematology #lymsm #MedEd #HemOnc (Twitter) - Jan 11, 2022
- ||||| mosunetuzumab (BTCT4465A) / Roche
Clinical: ✅ CD20 & CD3 bispecificAb, mosunetuzumab, well tolerated with durable complete response in relapsed/refractory indolent/aggressive #NonHodgkinLymphoma 👉 https://t.co/tOuiRNdT3W #NHL #JCO #lymsm @nancybartlettMD (Twitter) - Jan 5, 2022
- || Columvi (glofitamab-gxbm) / Roche, Lunsumio (mosunetuzumab-axgb) / Roche
Enrollment open: UPCC 48420: CAR-T Followed by Bispecific Antibodies (clinicaltrials.gov) - Jan 4, 2022
P2, N=42, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
The expansion stage of the study is ongoing at the dose level of 1/2/60/60/30 mg selected for further study. Not yet recruiting --> Recruiting
- ||||| mosunetuzumab (BTCT4465A) / Roche
Clinical: Results, which were presented during a press briefing at the 2021 ASH Annual Meeting, showed that mosunetuzumab elicited a complete response rate of 60% per IRF assessment. @elizabeth_budde @cityofhope @ASH_hematology #ASH21 #lymsm https://t.co/gKOFnmKUfj (Twitter) - Dec 29, 2021
- |||||||||| Polivy (polatuzumab vedotin-piiq) / Roche, Lunsumio (mosunetuzumab-axgb) / Roche, Rituxan (rituximab) / Roche
New P3 trial: SUNMO: A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Dec 28, 2021
P3, N=222, Not yet recruiting, Sponsor: Hoffmann-La Roche
- |||| mosunetuzumab (BTCT4465A) / Roche
Clinical: Fixed-duration treatment w/ mosunetuzumab induced deep responses w/ favorable tolerability in pretreated pts w/ R/R follicular lymphoma, meeting the primary end point of the GO29781 trial.@elizabeth_budde @cityofhope @ASH_hematology #ASH21 #lymsm https://t.co/o0C98kkEMO (Twitter) - Dec 27, 2021
- || Polivy (polatuzumab vedotin-piiq) / Roche, Lunsumio (mosunetuzumab-axgb) / Roche, Gazyva (obinutuzumab) / Roche, Biogen
New P2 trial: NCI-2021-12489: Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Dec 27, 2021
P2, N=42, Not yet recruiting, Sponsor: University of Washington
- ||| Columvi (glofitamab-gxbm) / Roche, Lunsumio (mosunetuzumab-axgb) / Roche
New P1 trial: CO43805: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Dec 27, 2021
P1, N=112, Not yet recruiting, Sponsor: Hoffmann-La Roche
- ||||| mosunetuzumab (BTCT4465A) / Roche
Clinical, Video: 🚨 Update from #ASH21 🚨 @DrMatasar shares his perspective on clinical implications of - POLARIX - CAR-T in LBCL (TRANSFORM, ZUMA-7, BELINDA) #tcellrx - Mosunetuzumab in FL Short video and slides now available: 👉https://t.co/rlHXRjjBM6👈 #lymsm #MedEd @ASH_hematology (Twitter) - Dec 22, 2021
- | mosunetuzumab (BTCT4465A) / Roche
Journal: Bispecific Antibody Takes Down FL. (Pubmed Central) - Dec 20, 2021
In a pivotal phase I/II trial, the investigational bispecific T-cell engaging antibody mosunetuzumab demonstrated high response rates, significantly bettering those historically seen with standard care in patients with relapsed/refractory follicular lymphoma. Drug maker Genentech announced it will file for FDA approval of mosunetuzumab to treat this form of non-Hodgkin lymphoma.
- ||||| mosunetuzumab (BTCT4465A) / Roche
Clinical, Video: 🚨 Update from #ASH21 🚨 @DrMatasar shares his perspective on clinical implications of - POLARIX - CAR-T in LBCL (TRANSFORM, ZUMA-7, BELINDA) #tcellrx - Mosunetuzumab in FL Short video and slides now available: 👉https://t.co/UyVzv69IDb👈 #lymsm #MedEd @ASH_hematology (Twitter) - Dec 20, 2021
- ||||| mosunetuzumab (BTCT4465A) / Roche
Clinical, Video: 🚨 Update from #ASH21 🚨 @DrMatasar shares his perspective on clinical implications of - POLARIX - CAR-T in LBCL (TRANSFORM, ZUMA-7, BELINDA) #tcellrx - Mosunetuzumab in FL Short video and slides now available: 👉https://t.co/rlHXRjjBM6👈 #lymsm #MedEd @ASH_hematology (Twitter) - Dec 20, 2021
- |||| mosunetuzumab (BTCT4465A) / Roche
Clinical: 👀 During #ASH2021, the #LymphomaHub was pleased to speak with @elizabeth_budde, @cityofhope. We asked, What results have you seen with mosunetuzumab in patients with high-risk #FL? 👉 https://t.co/0uVVdeLUlw 👈 #lymsm #lymphoma (Twitter) - Dec 15, 2021